Natural killer cells for immunotherapy

Your research matters.  We know the challenges and hurdles. That is why Miltenyi Biotec is committed to go with you every step of your ground-breaking research. Together, we work towards translating your findings into the clinic, quicker and easier with our wide variety of research, premium and GMP products.

NK MACS Medium and NK MACS GMP Medium have been optimized for the cultivation, activation and expansion of isolated human NK cells or NK cells from peripheral blood mononuclear cells (PBMCs). It is manufactured without animal-derived components and is fully translational.

• Superior NK cell expansion*
• Xeno-free
• Minimal growth of unwanted cells like B-, T-, and DC cells

_{*Supplementation with serum or autologous plasma is necessary}

Natural killer (NK) cells play a major role in immune surveillance and in the early immune response to cancer and infections¹^,². Beneficial anti-tumor responses have been observed, illustrating the safety profile and clinical potential of this treatment³^,⁴. With an increasing availability of anti-cancer drugs, the role of NK cell-based approaches in novel combination therapies has rapidly escalated⁵^,⁶.

The use of specific CliniMACS® Product Lines allows GMP-compliant manufacturing of NK cell products according to the needs given by a specific treatment concept.

Highly enriched NK cell products are generated by CD3 depletion followed by CD56 enrichment. A combined NK cell and natural killer T (NKT) cell product is produced by a single CD56 enrichment step. Heterogeneous NK cell products can be manufactured by either CD3 or TCRα/β depletion, optionally in combination with CD19 depletion is B cell depletion is required.

The latter two manufacturing strategies for NK cells allow co-enrichment of NK cells and accessory cells, such as monocytes and dendritic cells (CDs). In case of TCRα/β depletion γ/δ T cells are also preserved within the NK cell product.

References:

1.Chiossone, L. et al. (2018) Nat. Rev. Immunol. 18: 671–688.

2. Hammer, Q. et al. (2018) Nat. Immunol. 19: 800-808.

3. Miller, J. S. et al. (2005) Blood 105: 3051–3057.

4. Curti, A. et al. (2011) Blood 118: 3273–3279.

5. Bachanova, V. et al. (2018) Immunother. 67: 483-94.

6. Talleur, A. C. et al. (2017) Biol. Blood Marrow Transplant. 23: 1910–1917.